title: Choice, isolation, and preparation of cells for bioartificial vascular grafts.
abstract: Preparation of cells and tissues for bioartificial vascular grafts is discussed from the viewpoint of tissue engineering. In general, a neointima is not formed on vascular prostheses except at the anastomotic sites. Graft surfaces do not heal and are covered with fresh thrombi for a long period of time after implantation. The delayed healing is, so to speak, an intractable ulcer of the vascular wall. To overcome this problem, we have developed a tissue fragment transplantation method. We consider that neointima formation of vascular prostheses after implantation is a product of tissue engineering in vivo. Therefore, 3 essential elements for tissue engineering, i.e., cells, extracellular matrices, and cytokines, are required for neointima formation. Synthetic vascular prostheses lack one or more of these elements. In this study we demonstrated a standard healing process of fabric vascular prostheses and an antithrombogenic polymer graft using animal models. Then we showed the tissue fragment transplantation method using venous tissues, adipose tissues, and bone marrow. This method provided the 3 essential elements to the prostheses. To allow these elements to be actively engaged in neointima formation, we treated cells and tissues as clumps without enzymatic digestion. We also took advantage of the in vivo environment. With the results we demonstrate our way of thinking in relation to bioartificial vascular grafts.
authors.affiliation: First Department of Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Noishiki
authors.forename: Y
authors.initials: Y
authors.lastname: Yamane
authors.forename: T
authors.initials: T
authors.lastname: Okoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Tomizawa
authors.forename: S
authors.initials: S
authors.lastname: Satoh
mesh_terms: D000273:Adipose Tissue / Q000637:transplantation; D000818:Animals; D000933:Antifibrinolytic Agents; D001013:Aorta, Thoracic / Q000601:surgery; D001672:Biocompatible Materials; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods*; D016026:Bone Marrow Transplantation; D002469:Cell Separation; D004285:Dogs; D004730:Endothelium, Vascular / Q000502:physiology / Q000637:transplantation; D006085:Graft Survival; D006493:Heparin; D011093:Polyethylene Terephthalates; D011108:Polymers; D013927:Thrombosis / Q000517:prevention & control; D017539:Tunica Intima / Q000502:physiology / Q000637:transplantation; D014680:Veins / Q000637:transplantation
chemical_list: D000933:Antifibrinolytic Agents; D001672:Biocompatible Materials; D011093:Polyethylene Terephthalates; D011108:Polymers; D006493:Heparin